RA Capital β Full Portfolio
272 tracked investments Β· page 1 of 2 Β· listed companies and verified rows first
Freenome develops early-stage cancer detection technology using blood tests to identify cancer in its earliest, most treatable phases.
AI & Machine LearningBiotechDigital HealthHealthtechMedical DevicesLondon
Riley Ennis(Co-Founder and Chief Product Officer)Stuart Lawson(Director)Charles Roberts(Director)Gabriel Otte(Director)
Clinical stage oncology company developing cancer drugs paired with companion diagnostics; went public on NASDAQ (ACRV) in 2022.
Watertown, US
Board seatDerek DiRoccoΒ· per SEC Form D
BiotechSan Diego, US
Jonathan Leff(Director)Richard Lowenthal(Executive Officer, Director)Pratik Shah(Director)
Board seatPeter KolchinskyΒ· per SEC Form D
Palo Alto, US
Janice Drew(Executive Officer)David Cohen(Director)Robert Hopfner(Director)Gregory Moss(Executive Officer)Eugene Bauer(Executive Officer, Director)Francois Beaubien(Director)
Board seatDerek DiRoccoΒ· per SEC Form D
Clinical-stage biopharmaceutical company committed to developing best-in-class novel therapy for hypertension treatment.
BiotechRadnor, US
Adam Levy(Executive Officer)Srinivas Akkaraju(Director)Alexander Asam(Director)
BoardBrian Taylor Slingsby(Director)Olivier Litzka(Director)
Board seatDerek DiRoccoΒ· per SEC Form D Β· $118M raise Β· filed Jun 2022
BiotechCambridge, US
Patrick Vink(Director)Milind Deshpande(Director)Jean-Francois Formela(Director)Casper Breum(Director)Ankit Mahadevia(Executive Officer, Director)Stephen Garbacz(Executive Officer)
Board seatReza HalseΒ· per SEC Form D
Natera develops genetic tests and diagnostics using cell-free DNA technology to detect diseases including cancers, genetic disorders, and transplant-related conditions.
BiotechDigital HealthHealthtechMedical Devices
Matthew Rabinowitz(Co-founder & Executive Chairman)
Aclaris develops investigational monoclonal antibodies and small-molecule inhibitors targeting immune pathways for the treatment of atopic, autoimmune, and respiratory diseases.
BiotechHealthtechMedical DevicesWayne, US
Neal Walker(Executive Officer, Director)Joseph Monahan(Executive Officer)Hugh Davis(Executive Officer, Director)James Loerop(Executive Officer)Kevin Balthaser(Executive Officer)Kamil Ali-Jackson(Executive Officer)
HealthtechLaguna Hills, US
Andrew Wade(Executive Officer)Michael Zhao(Director)Olav Bergheim(Executive Officer, Director)James Cox(Director)
BiotechAustin, US
Charles N. York(Executive Officer)David G. Lowe(Executive Officer, Director)Henry Skinner(Director)George Georgiou(Director)Armen Shanafelt(Director)
Aktis Oncology discovers and develops targeted radiopharmaceuticals for treating solid tumors.
BiotechHealthtechMedical DevicesBoston, US
Todd Foley(Co-founder and Chairman)Patrick Baeuerle(Co-founder & Advisor)Shulamit Ron-Bigger(Executive Officer)
BoardHelen S. Kim(Director)Oleg Nodelman(Director)Andrew Levin(Director)
Apogee Therapeutics develops novel antibody therapeutics targeting biological drivers of inflammatory and immune diseases, aiming to improve on the standard of care.
Biotech
BiotechWestlake Village, US
Alexander Asam(Director)Ricky Sun(Director)Jonathan Silverstein(Director)Todd Franklin Watanabe(Executive Officer, Director)
BoardPatrick Heron(Director)Daniel Estes(Director)
BiotechBoston, US
Bruno Lucidi(Director)Jean-Pierre Sommadossi, Ph.D.(Executive Officer, Director)Evgeny Zatsev(Director)Frank Yu(Director)Gerald Chan(Director)Bruce Polsky(Director)
BIOAGE develops therapies targeting the molecular pathways that drive aging to increase healthspan and address age-related chronic diseases.
BiotechHealthtechLongevityRichmond, US
Kristen Fortney, PhD(Co-Founder, CEO)Eric Morgen, MD(Co-Founder, COO)Eric Morgen(Director)Dov Goldstein(Executive Officer)Jason Coloma(Director)Kristen Fortney(Executive Officer, Director)
Boundless Bio develops precision oncology medicines targeting ecDNA-amplified cancers, specifically creating a new category of ecDNA-directed therapies for patients with oncogenic alterations.
BiotechMedical DevicesLa Jolla, US
Benjamin Cravatt, Ph.D.(Director)Ho Sung Cho, Ph.D.(Director)Carolyn Ng, Ph.D.(Director)Jakob Loven, Ph.D.(Director)Zachary D. Hornby(Executive Officer, Director)Jonathan E. Lim, M.D.(Director)
C4 Therapeutics develops small molecule medicines called degraders that use targeted protein degradation (TPD) to eliminate disease-causing proteins via the body's ubiquitin proteasome system.
BiotechCambridge, US
Marc Cohen(Executive Officer, Director)Jason Fisherman(Executive Officer, Director)Miles Stuchin(Director)William M. Scalzulli(Director)Kenneth Anderson(Director)Malcolm S. Salter(Director)
Ceribell develops a point-of-care EEG system that uses AI to detect seizure activity, including status epilepticus, in patients.
AI & Machine LearningHealthtechMedical DevicesSunnyvale, US
Joseph Taylor(Director)Scott Blumberg(Executive Officer)Lucian Iancovici(Director)Raymond Woo(Executive Officer)Josef Parvizi(Director)David Stoffel(Executive Officer)
BiotechCambridge, US
Sara Nayeem(Director)Barbara Dalton(Director)David Mott(Director)Robert Hopfner(Director)Mette Kirstine Agger(Director)James G. McArthur(Executive Officer, Director)
Helicons develops a peptide-based therapeutic platform designed to target intracellular proteins previously considered undruggable by combining the specificity of antibodies with the cell-penetrating properties of small molecules.
AI & Machine LearningBiotechDeep TechMedical Devices
Mathai Mammen(CEO, President and Chairman)
Precision BioSciences is a clinical-stage biotechnology company developing genome-editing therapies based on its ARCUS platform.
BiotechDeep TechHealthtechDurham, US
JEFF SMITH(Executive Officer)DEREK JANTZ(Executive Officer, Director)MATTHEW KANE(Executive Officer, Director)TODD MELBY(Executive Officer)BEN AUSPITZ(Director)Jeff Smith(Co-founder)
Boston, US
Scribe is a molecular engineering company developing CRISPR-based genetic therapies to treat cardiometabolic disease and other conditions.
BiotechDeep TechHealthtechMedical DevicesBerkeley, US
Benjamin Oakes(Founder & CEO)Jennifer A. Doudna, PhD(Co-founder, Scientific Advisor)Benjamin L. Oakes, PhD(Co-founder, President and CEO)David F. Savage, PhD(Co-founder, Scientific Advisor)Brett Staahl, PhD(Co-founder, VP of External Innovation)
BoardVijay Pande(Director)
Seres Therapeutics is a clinical-stage biotechnology company developing therapies composed of rationally selected live bacterial consortia to treat serious diseases through modulation of the human microbiome.
BiotechDigital HealthHealthtechMedical DevicesCambridge, US
Matthew Henn(President and Chief Scientific Officer)
BiotechCharlestown, US
Lynne Sullivan(Director)Adam Koppel(Director)Stephen DiPalma(Executive Officer)Martin Freed(Director)Alexander (Bo) Cumbo(Executive Officer, Director)Paul Herizch(Executive Officer)
SpyGlass Pharma develops a sustained drug delivery system, the BIM-IOL System, that integrates long-acting glaucoma therapy into cataract surgery.
BiotechHealthtechMedical DevicesAliso Viejo, US
Malik Kahook(Executive Officer, Director)Patrick Mooney(Executive Officer, Director)Glenn Sussman(Executive Officer, Director)
BoardJake Merrill(Director)Geoff Pardo(Director)Bilal Khan(Director)
Vaxcyte develops broad-spectrum vaccines to prevent bacterial infections, using a cell-free protein synthesis platform and synthetic chemistry techniques.
BiotechHealthtech
Xilio (Xilio Therapeutics) is a clinical-stage biotechnology company developing tumor-selective immunotherapies, including checkpoint inhibitors, T cell engagers and related molecules, for the treatment of cancer.
BiotechHealthtechWaltham, US
Paul Clancy(Director)Daniel Curran(Director)Nancy Hong(Director)Rachel Humphrey(Director)Daniel Lynch(Director)Michael Ross(Director)
Bambusa Therapeutics develops bispecific antibodies for immunological and inflammatory (I&I) disorders, using antibody engineering to target multiple I&I indications.
BiotechHealthtechMedical DevicesAustin, US
Shanshan Xu(Founder & Chief Executive Officer)Helmut Jeggle(Co-Founder)Thang Ho(Chief Development Officer)Crystal MacKay(Chief Operating Officer)
Board seatDerek DiRoccoΒ· per SEC Form D
Outpace Bio develops engineered protein technologies and cell therapies to treat solid tumors, focusing on protein design and T cell engineering to improve cancer treatment efficacy and safety.
BiotechDeep TechMedical DevicesSeattle, US
Marc Lajoie(Co-founder & Chief Executive Officer)Scott Boyken(Co-founder & Chief Technology Officer)Stanley Riddell(Co-Founder and Scientific Advisor)Aaron Foster(Executive Officer)Charity Scripture(Executive Officer)Eric Soller(Executive Officer)
Board seatJake SimsonΒ· per SEC Form D
Stipple Bio develops targeted oncology therapies that act on tumor-specific cell surface epitopes to expand druggable targets and improve therapeutic index for cancer patients.
BiotechHealthtechCambridge, US
Aaron Ring(Co-founder)Aashish Manglik(Co-founder)Jeff Landau(Chief Executive Officer)Roland Gendron(Chief Business Officer)Michelle Zhang(Chief Scientific Officer)
BoardVineeta Agarwala(Director)
Board seatDerek DiRoccoΒ· per SEC Form D
Abcuro is a clinical-stage biopharmaceutical company developing ulviprubart, a monoclonal antibody that selectively depletes highly cytotoxic T cells by targeting the KLRG1 receptor.
BiotechHealthtechNewton, US
John Alexander Martin(Executive Officer, Director)Stefano Gulla(Executive Officer)Ryan Berry(Director)Donald McCarthy(Director)John Edwards(Director)Yajun Xu(Director)
Alchemab operates a platform that identifies novel drug targets and therapeutics by analyzing patient antibody repertoires using deep B cell sequencing and computational analysis of samples from disease-resilient individuals.
AI & Machine LearningBiotechDeep TechHealthtech
Jane Osbourn(Chief Executive Officer)
Avalanche Energy develops compact fusion technology to generate high-energy neutrons for materials testing, radioisotope production, and advanced nuclear battery systems serving defense, space, and commercial power applications.
Deep TechDefense TechEnergyRichland, US
Robin Langtry
Hyku Biosciences develops covalent medicines to improve patient outcomes by advancing the scientific boundaries of this therapeutic approach.
BiotechDeep TechMedical DevicesBurlington, US
KLEEM CHAUDHARY(Executive Officer, Director, Promoter)Kleem Chaudhary, PhD(President & CEO)Ku-Lung (Ken) Hsu, PhD(Endowed Associate Professor of Chemistry)
BoardJOHN GUSTOFSON(Director)LAURA BRASS(Director)LAURA TADVALKAR(Director)
Kinaset Therapeutics is a biopharmaceutical company developing respiratory drug therapies.
BiotechHealthtechMedfield, US
Tom King(Director of the Issuer)Roger Heerman(Chief Business/Operating Officer / Co-Founder)Frazer Morgan(Chief Development Officer / Co-Founder)Bram Vanparys(Director of the Issuer)Robert Clarke(Chief Executive Officer / Board Member / Co-Founder)Christopher OβBrien(Chief Medical Officer)
Sydnexis is a privately held biopharmaceutical company developing SYD-101, a proprietary low-dose atropine formulation in Phase 3 clinical trials to slow the progression of pediatric progressive myopia.
BiotechDigital HealthDel Mar, US
Patrick Johnson(Executive Officer, Promoter)Mary Jaqueline Johnson(Executive Officer)Mary Jacqueline Johnson(Executive Officer)Kevin Johnson(Director)Greg Ostrow(Executive Officer, Director)Kenneth Widder(Executive Officer, Director)
Vivace Therapeutics is an oncology-focused drug discovery and development company creating small-molecule inhibitors targeting the Hippo-YAP pathway to treat cancers including mesothelioma, meningioma, and various other tumor types.
BiotechHealthtechMedical DevicesSan Mateo, US
Shuang Qiao(Executive Officer, Director)Sheng Ding(Executive Officer)
BoardEdward Hu(Director)Jun Wu(Director)Jake Simson(Director)Tim Shannon(Director)
Structure-based small-molecule drug design targeting protein aggregation diseases.
BiotechThousand Oaks, US
Gary Wilcox(Director)James Treanor(Also a former CEO)John Frank(Director)Madhavan Balachandran(Executive Officer, Director)
Board seatReza HalseΒ· per SEC Form D Β· $6M raise Β· filed Dec 2020
HealthtechCambridge, US
Clarence Friedman(Executive Officer, Director)
Board seatPeter KolchinskyΒ· per SEC Form D Β· $3.1M raise Β· filed Sep 2017
BiotechTucson, US
Jon Faiz Kayyem, Ph.D.(Director)Louis Breton(Executive Officer, Director)David Baltimore, Ph.D.(Director)Harry A. George(Director)Bhavin Raval(Executive Officer)David H. Donabedian, Ph.D.(Director)
Board seatPeter KolchinskyΒ· per SEC Form D
BiotechCambridge, US
Philip Kantoff(Executive Officer, Director)Neil Bander(Executive Officer, Director)Eric Sullivan(Executive Officer)Alexander Brown(Executive Officer)
BoardTal Zaks(Director)
Board seatJake SimsonΒ· per SEC Form D Β· $99.2M raise Β· filed May 2023
BiotechSouth San Francisco, US
Jeremy Bender(Executive Officer, Director)Julie Papanek Grant(Director)Natalie Holles(Director)Daniel Becker(Director)
BoardMichael Gladstone(Director)
Board seatDerek DiRoccoΒ· per SEC Form D Β· $130M raise Β· filed Feb 2021
Menlo Park, US
Michael Rabson(Executive Officer, Promoter)Kevin Judice(Executive Officer, Promoter)
Board seatJake SimsonΒ· per SEC Form D Β· $81.5M raise Β· filed Jan 2021
Philadelphia, US
Charles Roberts(Director)Gabriel Otte(Executive Officer, Director)
Board seatPeter KolchinskyΒ· per SEC Form D Β· $300M raise Β· filed Dec 2021
G1 Therapeutics develops cancer therapies focused on improving patient outcomes and quality of life for people with cancer.
BiotechResearch Triangle Park, US
Timothy Sullivan(Director)Mark A. Velleca(Executive Officer, Director)Glenn Muir(Director)Gregory Mossinghoff(Executive Officer)Seth Rudnick(Director)Ron Laufer(Director)
Board seatPeter KolchinskyΒ· per SEC Form D
BiotechSeattle, US
Charles Richardson(Senior Vice President, Technical Operations)Mark McDade(Director)Terry Gould(Director)Adam K. Simpson(President and Chief Executive Officer)Eric Moessinger(Director)Niranjan Kanesa-thasan(Chief Medical Officer)
Board seatPeter KolchinskyΒ· per SEC Form D
Wakefield, US
BoardJoshua S. Phillips(Executive Officer, Director)Darshana Zaveri(Director)
Board seatPeter KolchinskyΒ· per SEC Form D Β· $3M raise Β· filed Aug 2017
BiotechBoston, US
William Daley Bonificio(Executive Officer, Promoter)Stephen Basil Thomas(Executive Officer, Director, Promoter)Naveen Manu Daryani(Executive Officer)
BoardGianna Hoffman-Luca(Director)
Board seatAndrew LevinΒ· per SEC Form D Β· $45M raise Β· filed Feb 2026
Privately-held biotech company developing biologic therapies for retinal diseases
BiotechBoston, US
William Daley Bonificio(Executive Officer, Promoter)Megan Krench(Director)Stephen Basil Thomas(Executive Officer, Promoter)Naveen Manu Daryani(Executive Officer, Director, Promoter)Vishal Kapoor(Director)
Board seatZach ScheinerΒ· per SEC Form D
BiotechWaltham, US
Qimin Quan(Executive Officer)Philippe Mourere(Executive Officer, Director)Joseph Wilkinson(Executive Officer)Scott Sherman(Executive Officer, Director)Elouise P. Manhertz(Executive Officer)
BoardJohn Boyce(Director)
Board seatAnurag KondapalliΒ· per SEC Form D Β· $4M raise Β· filed Mar 2025
BiotechRio Rancho, US
James Coffin(Executive Officer, Director)Michael Humbert(Executive Officer, Director, Promoter)Alexander Koglin(Executive Officer, Director, Promoter)
BoardDavid Seldin(Director)Edward Liddy(Director)
Board seatPeter KolchinskyΒ· per SEC Form D Β· $15M raise Β· filed May 2025
BiotechCharlottesville, US
Allen Cunningham(Executive Officer, Director)Nancy Hargreaves(Executive Officer)Jayson Dallas(Executive Officer, Director)Shaharyar Khan(Executive Officer, Director)Patrick Enright(Director)
BoardFrancesco De Rubertis(Director)
Board seatDerek DiRoccoΒ· per SEC Form D Β· $57M raise Β· filed Jan 2025
BiotechArlington, US
Daniel S. Grau(Executive Officer, Director)Scott L. Rakestraw(Director)
Board seatPeter KolchinskyΒ· per SEC Form D Β· $44M raise Β· filed Nov 2018
BiotechBoston, US
CAROLINE LOEW(Executive Officer, Director, Promoter)David Feltquate(Executive Officer)Maiken Keson-Brookes(Executive Officer)
BoardJULIE GRANT(Director)
Board seatEmily MinkowAndrew LevinΒ· per SEC Form D Β· $298.4M raise Β· filed Mar 2026
BiotechWaltham, US
CATHERINE RIESEN(Executive Officer)CONY D'CRUZ(Executive Officer, Director, Promoter)CRAIG RANDALL(Executive Officer)
BoardDIAMANTIS XYLAS(Director)DYLAN MORRIS(Director)
Board seatAndrew LevinΒ· per SEC Form D Β· $5M raise Β· filed Aug 2025
BiotechCambridge, US
Livio Valenti(Executive Officer)Kathryn Kosuda(Executive Officer, Director)Matthew Dirckx(Executive Officer)Lynda Tussey(Executive Officer)John Spiridigliozzi(Executive Officer)Weiner Tilsner(Executive Officer)
Board seatPeter KolchinskyΒ· per SEC Form D Β· $10M raise Β· filed Feb 2025
Werewolf Therapeutics is a biotechnology company developing immunotherapy treatments for cancer.
BiotechHealthtechMedical DevicesWatertown, US
Daniel J. Hicklin(Founder, President, Chief Executive Officer, and Board member)Luke Evnin(Co-founder, Board member (Chairman))Daniel Hicklin(Executive Officer, Director)Alon Lazarus(Director)David Cordo(Executive Officer)
BoardChristoph Westphal(Director)
Board seatDerek DiRoccoΒ· per SEC Form D
Adcendo develops antibody-drug conjugates (ADCs) targeting cancers with high unmet medical need.
BiotechMedical Devices
Aiolos Bio is a biopharma company that discovers, develops, and delivers medicines and vaccines across respiratory, immunology, inflammation, oncology, HIV, and infectious diseases.
BiotechHealthtech
BiotechBrookline, US
Emmanuel Simons(Executive Officer, Director)Kush Parmar(Director)
BoardEd Mathers(Director)
Alpha-9 Oncology develops radiopharmaceuticals for cancer treatment, with a portfolio of molecules in clinical and preclinical development.
BiotechDigital HealthMedical DevicesVancouver, CA
François Bénard(MD)Kuo-Shyan Lin(PhD)David Perrin(PhD)
AltruBio develops antibody-based therapeutics for immunological and inflammatory diseases, with clinical-stage candidates (ALTB-268 and ALTB-168) targeting conditions such as ulcerative colitis, psoriatic arthritis, psoriasis, and acute graft versus host disease.
BiotechHealthtech
Ambagon develops small molecule stabilizers of 14-3-3 protein complexes to modulate disease-related protein interactions, targeting therapeutic areas including cancer, metabolic disorders, neurodegenerative and infectious diseases.
BiotechDeep TechMedical DevicesEindhoven, US
Christian Ottmann(Executive Officer)Josh Seidenfeld(Executive Officer)Michelle Arkin(Director)Nancy Pryer(Executive Officer)Margarita Chavez(Director)Bryan Miller(Executive Officer)
Ansa provides an enzymatic DNA synthesis platform that directly synthesizes complex sequences up to 900 bp and delivers constructs up to 50 kb without assembly-based methods.
BiotechDeep TechHealthtechEmeryville, US
Dan Lin-Arlow(Founder)inSebastian Palluk(Founder)inDaniel Lin-Arlow(Executive Officer, Director)Jason T. Gammack(Executive Officer, Director)Daniel Hillel Lin-Arlow(Executive Officer, Director)
BoardYanniv Dorone(Director)
Apeiron Labs develops autonomous underwater vehicles and ocean technology for marine applications.
Climate TechDeep TechIoTRoboticsCambridge, US
Ravi Pappu(CEO / Board Member)
BoardSanjeev Krishnan(Director)Jonathan Rosen(Director)David Douglas(Director)Kyle Teamey(Director)Mark Abbott(Director)
Ascendis Pharma is a biopharmaceutical company developing therapies for hormone-related disorders and rare diseases.
BiotechHealthtechMedical DevicesDenmark, DK
Jan MΓΈller Mikkelsen(Founder, President and Chief Executive Officer)
BiotechSan Francisco, US
Steve Squinto(Director)Kush Parmar(Director)Matthew Patterson(Executive Officer, Director)Thomas Woiwode(Director)Louis G. Lange(Director)Thomas Schuetz(Director)
Avilar develops protein degrader drugs targeting extracellular and membrane-bound proteins, using a novel class called ATACs that harness endolysosomal degradation machinery.
AI & Machine LearningBiotechMedical DevicesWaltham, US
THERESA CAMERON(Director)MARTIN FREED(Director)STEPHANIE TOZZO(Executive Officer)PHIL GRAHAM(Executive Officer)MILIND DESHPANDE(Director)DAVID NEAFUS(Executive Officer)
Azalea Therapeutics develops precision genome editing therapies that engineer T cells directly inside the patient's body to create cancer immunotherapies, using proprietary delivery vehicles to target and modify specific genetic loci without ex vivo cell manipulation.
AI & Machine LearningBiotechMedical DevicesSan Francisco, US
Jennifer Doudna(Co-founder, Nobel Laureate in Chemistry and Li Ka Shing Chancellor's Chair in Biomedical and Health Sciences, UC Berkeley)Rodolphe Barrangou(Co-founder, Associate Professor of Medicine, UCSF)Krishnendu Roy(Co-founder, Professor of Bioengineering, Stanford University)Connor Tsuchida(Scientific Cofounder)
Clinical-stage biopharmaceutical company developing controllable cell therapies, including next-generation CAR-T, TCR and allogeneic T cell products such as rivo-cel and the GoCAR-T candidate BPX-601.
Genetix Biotherapeutics (formerly bluebird bio) develops gene therapies for patients with rare genetic diseases including sickle cell disease, beta-thalassemia, and cerebral adrenoleukodystrophy.
BiotechLongevityMedical DevicesCambridge, US
David Meek(Chief Executive Officer)Brian Riley(President & Chief Technical Officer)Joanne Lager(Chief Medical Officer)Wendy DiCicco(Chief Financial Officer)Adrian Chaisson(Chief of Staff)Daniel S. Lynch(Director)
Healthcare company acquired by Mirum Pharmaceuticals, a former RiverVest portfolio company.
San Mateo, US
Keting Chu(Executive Officer, Director)Dajun Yang(Director)Nancy Hong(Director)Alon Lazarus(Director)William J. Rutter(Director)Ting Jia(Director)
San Diego, US
Fredrik Wiklund(Executive Officer, Director)Christine Siu(Director)Michael Rosenzweig(Director)Bertolt Kreft(Executive Officer)Alexander Mayweg(Director)Josh Resnick(Director)
BiotechSan Diego, US
Justin Thacker(Executive Officer)Karen Smith(Director)Fabio Pucci(Director)Adrian Bot(Executive Officer)Michal Silverberg(Director)Laura Shawver(Executive Officer, Director)
Pharmaceutical company developing medicines and vaccines for patient health and treatment.
BiotechHealthtechSan Diego, US
Jeffrey Stein(Executive Officer, Director)Steve Elms(Director)Dan Burgess(Director)Ted Schroeder(Director)Kevin Forrest(Executive Officer)Dirk Thye(Executive Officer)
BiotechCharlottesville, US
Kevin S Eisenfrats(Executive Officer, Director, Promoter)Iris Van Alderwerelt van Rosenburgh(Director)Martin J Emerson(Director)Tom Thorpe(Director)Michael King(Director)
BoardGurdane Bhutani(Director)
PartnerLaura StoppelΒ· quoted
Convergent provides an AI simulation platform for enterprise training and skill development.
AI & Machine LearningEnterprise SoftwareHR TechSaaSLondon, GB
Nasdaq: CTKB.
Dignify Therapeutics develops "on demand" drugs that trigger emptying of the bladder and/or bowel when a person chooses, aimed at restoring control of bowel and bladder function.
BiotechDigital HealthMedical DevicesResearch Triangle Park, US
Karl B Thor(Executive Officer, Director, Promoter)Edward C Burgard(Executive Officer, Director, Promoter)Benny Ward(Executive Officer, Director, Promoter)Daniel J Ricca(Director, Promoter)Ebrahim Versi(Director, Promoter)Karl Thor
Novartis is a pharmaceutical company with a history spanning 250 years of scientific innovation.
BiotechSan Diego, US
Arthur T Suckow(Executive Officer)
BiotechSan Francisco, US
JONATHAN FOX(Executive Officer)UMA SINHA(Executive Officer)HOYOUNG HUH(Director)NEIL KUMAR(Executive Officer, Director)ERIC AGUIAR(Director)CHRISTINE SIU(Executive Officer)
Electra Therapeutics develops antibody therapeutics targeting Signal Regulatory Protein (SIRP) for immunological diseases and cancer treatment.
BiotechHealthtechMedical DevicesSouth San Francisco, US
Quehuong (Kathy) Dong, Pharm.D.(Executive Officer, Director)
BoardBeth Seidenberg, M.D.(Director)Thomas Geninatti, Ph.D.(Director)Carl Gordon, Ph.D.(Director)Matthew Fust(Director)Nancy Stagliano, Ph.D.(Director)
Element Biosciences develops biological analysis platforms and DNA sequencing tools for scientists and research institutions.
BiotechDeep TechHardwareMedical Devices
European biopharmaceutical company advancing a nectin-4 antibody-drug conjugate for solid tumour oncology.
Empatica develops software and algorithms that monitor neurological patients through wearable sensors, providing real-time physiological and behavioral biomarkers to patients, clinicians, and researchers.
AI & Machine LearningDigital HealthHealthtechMedical DevicesCambridge, US
Rosalind Picard(Founder and Director of the Affective Computing Group at the MIT Media Lab and Faculty Chair, MIT Mind+Hand+Heart Wellbeing Initiative)Matteo Lai(Executive Officer, Director)Mario Scuderi(Director)Simone Tognetti(Director)
Farcast develops advanced satellite communication user terminals with flat panel phased array antennas that electronically track satellite movement for reduced size, weight, power, and cost.
Advanced ManufacturingHardwareSpace TechSan Francisco, US
Siamak Ebadi(Founder)in
BoardDavid Byrd(Director)Guido Jouret(Director)
Forge Biologics provides contract manufacturing and process development for AAV-based gene therapies, operating a large-scale cGMP facility with proprietary manufacturing technologies to support developers from early discovery through commercial production.
Advanced ManufacturingBiotechMedical DevicesGrove City, US
Chris Garabedian(Director)Timothy J. Miller(Executive Officer, Director)
BoardMolly McCartin(Director)
Frontier Meds develops small-molecule drugs targeting previously undruggable protein targets using a proprietary approach to identify and exploit novel binding sites across the human proteome.
BiotechSouth San Francisco, US
Jim Winkler(Executive Officer)Johannes Hermann, Ph.D.(Executive Officer)Kevin Webster(Executive Officer)Cameron Wheeler(Director)Gregory Chow(Executive Officer)Chris Varma, Ph.D.(Executive Officer, Director)
Gameto develops cell therapy and reproductive technologies to treat infertility and improve women's health outcomes.
BiotechFemTechHealthtechMedical DevicesAustin, US
Dina Turner(Co-founder & Chief Executive Officer)inMartin Varsavsky(Co-founder & Chairman)inDusan Perovic(Director)Dina Radenkovic(Executive Officer, Director)Dylan Morris(Director)
BoardMaryanna Saenko(Director)
South San Francisco, US
John Schembri(Executive Officer)Charles Homcy, M.D.(Director)Ted W. Love(Executive Officer, Director)
BoardKevin Starr(Director)
Halda provides AI-powered agents for student recruitment and enrollment management at educational institutions.
AI & Machine LearningEdTechSaaSProvo, US
Lance Hydrick(Executive Officer, Director)Dallin Palmer(Director)
BoardSid Krommenhoek(Director)
BiotechMedical DevicesNew Haven, US
Scott Phillips(Executive Officer)Leyi Wang(Manager)Rebecca Frey(Manager)
BoardTim Shannon(Manager)Liam Ratcliffe(Manager)
BiotechWeston, US
Keith Rubin(Executive Officer, Director)William Steinkrauss(Executive Officer)KEN SOLOVAY(Executive Officer)
BoardEric Edidin(Director)Avi Naider(Director)Mario Barro(Director)
Inhibrx Biosciences, Inc. is a biotechnology company that was spun off as a subsidiary of Inhibrx, Inc. through a pro rata distribution of shares to shareholders.
BiotechLa Jolla, US
Mark Lappe(Executive Officer, Director)Doug Forsyth(Director)Brendan Eckelman(Director)Jon Faiz Kayyem(Director)Margery Fischbein(Director)
BoardJudith Li(Director)
Clinical-stage company developing tumor-activated immunotherapies using platform masking technology.
Clinical-stage biotech using its RAPID chemoproteomics platform to drug challenging targets; acquired by Otsuka in 2024.
Boston, US
Koloma explores and produces natural hydrogen to support global decarbonization efforts.
CleantechClimate TechDeep TechEnergyDenver, US
Peter Johnson(Executive Officer, Director)Jeff Knupp(Executive Officer)Bunmi Adekore(Executive Officer, Director)Paul Harraka(Executive Officer)
BoardChristian Garcia(Director)Shayle Kann(Director)
Merus develops multispecific antibodies (Biclonics and Triclonics) that bind multiple cancer antigens to treat oncology indications.
BiotechMedical DevicesUtrecht, NL
Mark Throsby(Executive Officer)Gregory D. Perry(Director)Mark T. Iwicki(Director)Lionel M.S. Carnot(Director)Hui Liu(Executive Officer)Wolfgang Berthold(Director)
A targeted approach for the control of hypertension
Moderna develops mRNA-based medicines for infectious and serious diseases using its proprietary mRNA platform and design technology.
BiotechDeep TechMedical DevicesCambridge, US
Lorence Kim(Executive Officer)Robert Langer(Director)Peter Hutt(Director)John Mendlein(Director)James R. Kasinger(Executive Officer)Elizabeth Nabel(Director)
Rows marked βSEC filingβ are inferred from directors named on the company's SEC Form D β public regulatory data, not a portfolio list published by the firm.